Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
February 21 2023 - 6:00AM
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a
clinical-stage biopharmaceutical company, today announced that it
will host a live conference call and audio webcast on Tuesday,
February 28, 2023, at 4:30 p.m. ET to report financial results for
the fourth quarter and full year ended December 31, 2022, and to
provide a business update.
To access the live conference call, participants may register
here. While not required, it is recommended that participants join
the call ten minutes prior to the scheduled start. A live webcast
of the call will also be available under "Events and Presentations"
in the Investor Relations section of the Atea Pharmaceuticals
website at ir.ateapharma.com. An archived webcast will be available
on Atea Pharmaceuticals’ website approximately two hours after the
conference call and will remain available for at least 90 days
following the event.
About Atea Pharmaceuticals
Atea is a clinical stage biopharmaceutical company focused on
discovering, developing and commercializing oral therapies to
address the unmet medical needs of patients with serious viral
diseases. Leveraging the Company’s deep understanding of antiviral
drug development, nucleos(t)ide chemistry, biology, biochemistry
and virology, Atea has built a proprietary nucleos(t)ide prodrug
platform to develop novel product candidates to treat single
stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent
cause of serious viral diseases. Atea plans to continue to build
its pipeline of antiviral product candidates by augmenting its
nucleos(t)ide platform with other classes of antivirals that may be
used in combination with its nucleos(t)ide product candidates.
Currently, Atea is focused on the development of orally-available
antiviral agents for serious viral infections, including severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus
that causes COVID-19, dengue virus and hepatitis C virus (HCV). For
more information, please visit www.ateapharma.com.
Forward-Looking
Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation statements regarding the timing of Atea’s
earnings call for the quarter ended December 31, 2022. These
statements are neither promises nor guarantees, but involve known
and unknown risks, uncertainties and other important factors that
may cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including, but not limited to the important factors
discussed under the caption “Risk Factors” in our Annual Report on
Form 10-K for the year ended December 31, 2021 and our other
filings with the SEC. Any such forward-looking statements represent
management’s estimates as of the date of this press release. While
we may elect to update such forward-looking statements at some
point in the future, we disclaim any obligation to do so, even if
subsequent events cause our views to change.
Contacts
Jonae BarnesSVP, Investor Relations and Corporate
Communications617-818-2985Barnes.jonae@ateapharma.com
Will O’ConnorStern Investor Relations
212-362-1200will.oconnor@sternir.com
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Jul 2024 to Jul 2024
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Jul 2023 to Jul 2024